Dapagliflozin as monotherapy or combination therapy in Japanese patients with type 2 diabetes: an open-label study (Q34726376)

4 August 2017

Dapagliflozin as monotherapy or combination therapy in Japanese patients with type 2 diabetes: an open-label study (English)

1 reference

4 August 2017

0 references

Kohei Kaku

1

1 reference

4 August 2017

Hiroshi Maegawa

2

1 reference

4 August 2017

Yukio Tanizawa

3

1 reference

4 August 2017

Arihiro Kiyosue

4

1 reference

4 August 2017

Yumiko Ide

5

1 reference

4 August 2017

Takuto Tokudome

6

1 reference

4 August 2017

Yuji Hoshino

7

1 reference

4 August 2017

Jisin Yang

8

1 reference

4 August 2017

Anna Maria Langkilde

9

1 reference

4 August 2017

24 October 2014

1 reference

4 August 2017

1 reference

4 August 2017

5

1 reference

4 August 2017

415-433

1 reference

4 August 2017

2

1 reference

Creative Commons Attribution 4.0 International

4 August 2017

start time

24 October 2014

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

exact match

https://scigraph.springernature.com/pub.10.1007/s13300-014-0086-7

0 references

cites work

Genital and urinary tract infections in diabetes: impact of pharmacologically-induced glucosuria

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4269643

Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4269643

Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetes

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4269643

Pharmacokinetics and pharmacodynamics of dapagliflozin, a novel selective inhibitor of sodium-glucose co-transporter type 2, in Japanese subjects without and with type 2 diabetes mellitus

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4269643

Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4269643

SGLT2 inhibition--a novel strategy for diabetes treatment

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4269643

A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4269643

Revised equations for estimated GFR from serum creatinine in Japan

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4269643

Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4269643

Active sugar transport in health and disease

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4269643

Achieving good glycemic control: initiation of new antihyperglycemic therapies in patients with type 2 diabetes from the Kaiser Permanente Northern California Diabetes Registry

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4269643

United Kingdom Prospective Diabetes Study 17: a 9-year update of a randomized, controlled trial on the effect of improved metabolic control on complications in non-insulin-dependent diabetes mellitus.

7 July 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13300-014-0086-7

Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13300-014-0086-7

Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13300-014-0086-7

Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13300-014-0086-7

Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13300-014-0086-7

Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13300-014-0086-7

Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13300-014-0086-7

Efficacy and safety of dapagliflozin as a monotherapy for type 2 diabetes mellitus in Japanese patients with inadequate glycaemic control: a phase II multicentre, randomized, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13300-014-0086-7

Efficacy and safety of dapagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13300-014-0086-7

Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13300-014-0086-7

Urinary tract infections in patients with diabetes treated with dapagliflozin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13300-014-0086-7

Vulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13300-014-0086-7

[Special issue: Clinical practice guidebook for diagnosis and treatment of chronic kidney disease 2012]

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25341477

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

[Japan Diabetes Society clinical practice guideline]

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25341477

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S13300-014-0086-7

1 reference

Dimensions Publication ID

4 August 2017

0 references

1 reference

4 August 2017

1 reference